Back in June, Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Qlt Inc.
Keep Reading →
September 14 - Hedge Funds, News - Comments
Markets opened higher on Wednesday as investors await the announcement regarding interest rate hike from the Federal Reserve today.
Keep Reading →
June 15 - Market Movers, News - Comments
U.S. stocks look set to end today's trading session in green territory, having gone through a strong selloff last week.
Keep Reading →
December 21 - Market Movers, News - Comments
Although the market has regained most of the losses from the opening hour, there are some stocks that have remained deep in red. Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ...
Keep Reading →
November 10 - Earnings Report, Market Movers, News, Tech - Comments
Alex Denner is still bullish on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and has further increased his stake in the company.
Keep Reading →
September 30 - Hedge Funds, News - Comments
According to a recent 13G form filed with the Securities and Exchange Commission, Kevin Kotler's Broadfin Capital has initiated a stake in ContraFect Corp (NASDAQ:CFRX) to the...
Keep Reading →
June 22 - Hedge Funds, News - Comments
To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross understatement.
Keep Reading →
April 16 - Hedge Funds, News - Comments
At Insider Monkey, we track over 700 of the top hedge funds in the world, following and reporting on their latest moves disclosed through filings with the Securities and Exchange...
Keep Reading →
April 2 - Hedge Funds, News - Comments
Kevin Kotler's New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).
Keep Reading →
November 7 - Hedge Funds, News - Comments
Steve Cohen’s Point72 Asset Management disclosed today a huge increase in its stake in Lumber Liquidators Holdings Inc (NYSE:LL). The funds affiliated with Mr.
Keep Reading →
October 16 - Hedge Funds, News - Comments
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds’ bullishness.
Keep Reading →
October 15 - Hedge Funds, News - Comments
Life science is turning out to be an industry sector that most hedgies are convinced will outperform in the near future.
Keep Reading →
October 15 - Hedge Funds, News - Comments
Scopia Capital Management has disclosed in a recent regulatory filing with the Security and Exchange Commission that it has acquired 4.2 million shares of Aegerion Pharmaceuticals...
Keep Reading →
August 12 - Hedge Funds, News - Comments
Over the past couple of days, the healthcare sector has witnessed plenty of insider activity, which should not be overlooked.
Keep Reading →
May 8 - Insider Trading - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best performing stocks in the ...
Keep Reading →
September 20 - News - Comments
Big Pharma gets plenty of hype.
Keep Reading →
September 17 - News - Comments
To the average investor, there are many methods market participants can use to analyze publicly traded companies.
Keep Reading →
September 17 - News - Comments
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur.
Keep Reading →
September 16 - News - Comments
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc.
Keep Reading →
September 11 - News - Comments
Make that four collaborations between Biogen Idec Inc. (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in the last two years.
Keep Reading →
September 10 - News - Comments
At the moment, there are tons of indicators shareholders can use to analyze publicly traded companies.
Keep Reading →
September 3 - News - Comments
Santarus, Inc. (NASDAQ:SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in the first quarter.
Keep Reading →
August 28 - News - Comments
To the average investor, there are dozens of gauges market participants can use to watch publicly traded companies.
Keep Reading →
August 26 - News - Comments
The Motley Fool's readers have spoken, and I have heeded their cries.
Keep Reading →
August 7 - News - Comments
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Keep Reading →
August 7 - News - Comments
In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC.
Keep Reading →
August 7 - News - Comments
Both ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Aegerion Pharmaceuticals, Inc.
Keep Reading →
August 5 - News - Comments
There are few times when your doctor or physician will utter the phrase, "I don't know" to a patient, but when you're dealing with the rarest of diseases, then all bets are off...
Keep Reading →
August 5 - News - Comments
The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases.
Keep Reading →
August 1 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
August 1 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don't have to imagine it.
Keep Reading →
July 5 - News - Comments
In the last couple of years, the biotechnology industry has been on a roll.
Keep Reading →
July 2 - News - Comments
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
Keep Reading →
June 27 - News - Comments
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
Keep Reading →
June 27 - News - Comments
Is Pacira Pharmaceuticals Inc (NASDAQ:PCRX) a superb investment right now? Hedge funds are in an optimistic mood.
Keep Reading →
June 12 - News - Comments
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
June 10 - News - Comments
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Keep Reading →
June 3 - News - Comments
Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 31 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
May 29 - News - Comments
According to most market participants, hedge funds are assumed to be underperforming, outdated financial tools of the past.
Keep Reading →
May 29 - News - Comments
Up, up, and away. That's the motto for the market as a whole so far this year, but it's also especially applicable for a select group of stocks.
Keep Reading →
May 20 - News - Comments
Shares of Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 20 - News - Comments
Wall Street had a great week. The Dow topped 15,000. The S&P 500 also notched a record high. But few stocks blew the doors off like those of these three biotech companies.
Keep Reading →
May 4 - News - Comments
Amgen, Inc. (NASDAQ:AMGN) stock has been on a bit of a roller coaster lately.
Keep Reading →
May 1 - News - Comments
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical Corp.
Keep Reading →
April 24 - News - Comments
Roche Holding Ltd. (ADR) (PINK:RHHBY) and ISIS Pharmaceuticals, Inc.
Keep Reading →
April 8 - News - Comments
An interesting method of assessing the direction a stock can take is by monitoring insider purchases.
Keep Reading →
March 28 - Insider Trading - Comments
On Monday, Depomed Inc (NASDAQ:DEPO) is expected to go before the FDA panel with its menopausal hot-flash drug, Serada.
Keep Reading →
March 4 - News - Comments
Orphan drugs -- medications meant for small patient populations with rare, dangerous diseases -- can be a rewarding business for biotech firms that strike gold.
Keep Reading →
February 22 - News - Comments